Cladribine (CLAD) Clinical Trials

2 recruitingDrug

Phase 22Phase 11

Filters

Status

RecruitingNot yet recruitingEnrolling by invitationActive, not recruiting

Sex

MaleFemale

Your Age

Shows trials you qualify for by age

Phase

Phase 1Phase 2Phase 3Phase 4Early Phase 1Not Applicable

Study Type

InterventionalObservational

Country

United StatesCanadaUnited KingdomAustraliaGermanyFranceSpainItaly

Related Interventions

Venetoclax208
Cytarabine103
Ruxolitinib65
Gilteritinib18
Olutasidenib10
Tagraxofusp6

Showing 1–2 of 2 trials

Recruiting

Phase 2

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Targeted TherapyIDH1-Mutated MalignanciesMutations

M.D. Anderson Cancer Center68 enrolled1 locationNCT07032727

Recruiting

Phase 1Phase 2

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia

Stanford University20 enrolled1 locationNCT06561152

ClinicalTrialsFinder

Helping patients and researchers find recruiting clinical trials. Updated regularly from ClinicalTrials.gov and ANZCTR.

Browse

Browse Conditions
Browse Drugs
Browse Locations
Browse Institutions
Search Trials
Get Trial Alerts

Resources

Clinical Trial Guides
FAQ
About Us
Contact
ClinicalTrials.gov
ANZCTR

Data Source

Trial data sourced from ClinicalTrials.gov and ANZCTR (Australian New Zealand Clinical Trials Registry)

Updated regularly to reflect the latest trial information

Medical Disclaimer: This site is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making decisions about participating in a clinical trial. Trial information may change; verify details directly with the trial sponsor or at the relevant registry (ClinicalTrials.gov or ANZCTR).

|

Privacy Policy Terms of Service

Data provided by ClinicalTrials.gov & ANZCTR